Aayush Wellness accepted the resignation of Managing Director Naveenakumar Kunjaru effective September 9, 2026. The departure follows personal and family commitments cited by the outgoing executive.

The company disclosed the change in leadership pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kunjaru, identified by DIN 07087891, tendered his resignation to the Board of Directors on September 8, 2026.

Leadership Transition Details

Kunjaru confirmed that there are no material reasons for his resignation other than those stated in his letter. The Board formally accepted the resignation with effect from September 9, 2026.

External Directorships

The filing noted Kunjaru’s current roles in other listed entities. He serves as a Non-Executive Independent Director at Empower India Limited. His responsibilities there include chairing the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee. He also sits as a member of the Risk Management Committee at Empower India.

Regulatory Compliance

Aayush Wellness submitted the disclosure to both BSE Limited and Metropolitan Stock Exchange of India Limited. The submission included Annexure I detailing the reasons for cessation and confirmation of no other material factors influencing the decision.

Aayush Wellness reported a significant scale-up in financial performance for FY26, with consolidated revenue from operations more than doubling year-on-year. The company delivered strong top-line growth while maintaining profitability, reflecting successful execution of its preventive healthcare strategy.

Financial Performance

Consolidated revenue from operations stood at ₹15,548.15 lakh for the year ended March 31, 2026, up from ₹7,334.57 lakh in FY25. This represents a robust 112% year-on-year growth. Total income, which includes other income, rose to ₹15,809.17 lakh, an increase of 115% compared to the previous fiscal year.

Profitability metrics showed steady improvement alongside the revenue expansion. Profit before tax (PBT) increased to ₹440.35 lakh from ₹337.49 lakh in FY25. Net profit after tax (PAT) grew by 18% to ₹398.04 lakh, up from ₹336.58 lakh in the prior year.

Operational Highlights

The company continued to expand its integrated preventive healthcare ecosystem. Aayush Wellness launched several new nutraceutical products, including Liver Detox Tablets, Brain Fuel Capsules, and Immunity Booster Tablets. These launches targeted specific health concerns such as liver health, cognitive function, and general immunity.

The firm also strengthened its diagnostics vertical through Aayush Labs. It entered into a strategic collaboration with Healthrashi Nextgen India Limited for AI-enabled healthcare infrastructure. Additionally, the company partnered with Blinkit to enhance its omnichannel distribution network via quick commerce platforms.

Dividend and Governance

During FY26, the company paid an interim dividend of ₹0.025 per equity share. The Board of Directors proposed the reappointment of Mr. Gavadu Patil as a director and the appointment of M/s. A. Raghavendra Rao & Associates as statutory auditors for five years.

The Secretarial Audit Report noted a delay in filling the casual vacancy caused by the resignation of the previous statutory auditor, M/s. A J M S & Co. LLP. The Board appointed the new auditors in May 2026, after the prescribed 30-day period.

What the Numbers Show

The divergence between revenue growth and net profit expansion highlights the investment phase of the business. While revenue surged 112%, net profit grew only 18%. This compression in net margin—from approximately 4.6% in FY25 to 2.5% in FY26—indicates that operating expenses and marketing costs scaled faster than earnings during this period of rapid top-line expansion.